Mylan Tries To Escape Pharmacy's EpiPen Antitrust Suit

By Meghan Kelly · December 15, 2020, 5:46 PM EST

Mylan Pharmaceuticals has urged a Kansas federal judge to drop it from a suit alleging it inflated the price for the emergency allergy medication EpiPen, arguing the retail and online pharmacy...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation

Case Number

2:17-md-02785

Court

Kansas

Nature of Suit

Personal Inj. Prod. Liability

Date Filed

August 04, 2017

Case Title

KPH Healthcare Services, Inc. v. Mylan N.V. et al

Case Number

2:20-cv-02065

Court

Kansas

Nature of Suit

Anti-Trust

Date Filed

February 14, 2020

Featured Stories

NC Litigation Highlights Of 2024: A Midyear Report No Photo Available

Hayley Fowler

Several high profile cases in North Carolina came to a close in the first half of the year, from a second bribery conviction against a... (more story)

CMS Takes Baby Steps In New 'Breakthrough' Device Policy No Photo Available

Theresa Schliep

The Centers for Medicare and Medicaid Services recently finalized highly anticipated guidance providing a new pathway for Medicare cov... (more story)

Test-Makers See Way Out Of FDA Rule With Chevron Reversal No Photo Available

Mark Payne

This spring, despite widespread industry opposition, the U.S. Food and Drug Administration granted itself oversight of laboratory-deve... (more story)